@article{nettifee_munana_griffith_2017, title={Evaluation of the Impacts of Epilepsy in Dogs on Their Caregivers}, volume={53}, ISSN={["1547-3317"]}, url={http://www.scopus.com/inward/record.url?eid=2-s2.0-85019011505&partnerID=MN8TOARS}, DOI={10.5326/jaaha-ms-6537}, abstractNote={ABSTRACT}, number={3}, journal={JOURNAL OF THE AMERICAN ANIMAL HOSPITAL ASSOCIATION}, author={Nettifee, Julie A. and Munana, Karen R. and Griffith, Emily H.}, year={2017}, pages={143–149} }
 @article{gieger_nettifee-osborne_hallman_johannes_clarke_nolan_williams_2017, title={The impact of carboplatin and toceranib phosphate on serum vascular endothelial growth factor (VEGF) and metalloproteinase-9 (MMP-9) levels and survival in canine osteosarcoma}, volume={81}, number={3}, journal={Canadian Journal of Veterinary Research}, author={Gieger, T. L. and Nettifee-Osborne, J. and Hallman, B. and Johannes, C. and Clarke, D. and Nolan, M. W. and Williams, L. E.}, year={2017}, pages={199–205} }
 @article{munana_nettifee-osborne_papich_2015, title={Effect of Chronic Administration of Phenobarbital, or Bromide, on Pharmacokinetics of Levetiracetam in Dogs with Epilepsy}, volume={29}, ISSN={["1939-1676"]}, url={http://www.scopus.com/inward/record.url?eid=2-s2.0-84925714278&partnerID=MN8TOARS}, DOI={10.1111/jvim.12548}, abstractNote={BackgroundLevetiracetam (LEV) is a common add‐on antiepileptic drug (AED) in dogs with refractory seizures. Concurrent phenobarbital administration alters the disposition of LEV in healthy dogs.}, number={2}, journal={JOURNAL OF VETERINARY INTERNAL MEDICINE}, author={Munana, K. R. and Nettifee-Osborne, J. A. and Papich, M. G.}, year={2015}, pages={614–619} }
 @article{schwartz_munana_nettifee-osborne_2013, title={Assessment of the prevalence and clinical features of cryptogenic epilepsy in dogs: 45 cases (2003-2011)}, volume={242}, ISSN={["1943-569X"]}, url={http://www.scopus.com/inward/record.url?eid=2-s2.0-84873910001&partnerID=MN8TOARS}, DOI={10.2460/javma.242.5.651}, abstractNote={Abstract}, number={5}, journal={JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION}, author={Schwartz, Malte and Munana, Karen R. and Nettifee-Osborne, Julie}, year={2013}, month={Mar}, pages={651–657} }
 @article{schwartz_munana_nettifee-osborne_messenger_papich_2013, title={The pharmacokinetics of midazolam after intravenous, intramuscular, and rectal administration in healthy dogs}, volume={36}, ISSN={["0140-7783"]}, url={http://www.scopus.com/inward/record.url?eid=2-s2.0-84883647308&partnerID=MN8TOARS}, DOI={10.1111/jvp.12032}, abstractNote={Intravenous benzodiazepines are utilized as first‐line drugs to treat prolonged epileptic seizures in dogs and alternative routes of administration are required when venous access is limited. This study compared the pharmacokinetics of midazolam after intravenous (IV), intramuscular (IM), and rectal (PR) administration. Six healthy dogs were administered 0.2 mg/kg midazolam IV, IM, or PR in a randomized, 3‐way crossover design with a 3‐day washout between study periods. Blood samples were collected at baseline and at predetermined intervals until 480 min after administration. Plasma midazolam concentrations were measured by high‐pressure liquid chromatography with UV detection. Rectal administration resulted in erratic systemic availability with undetectable to low plasma concentrations. Arithmetic mean values ± SD for midazolam peak plasma concentrations were 0.86 ± 0.36 μg/mL (C0) and 0.20 ± 0.06 μg/mL (Cmax), following IV and IM administration, respectively. Time to peak concentration (Tmax) after IM administration was 7.8 ± 2.4 min with a bioavailability of 50 ± 16%. Findings suggest that IM midazolam might be useful in treating seizures in dogs when venous access is unavailable, but higher doses may be needed to account for intermediate bioavailability. Rectal administration is likely of limited efficacy for treating seizures in dogs.}, number={5}, journal={JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS}, author={Schwartz, M. and Munana, K. R. and Nettifee-Osborne, J. A. and Messenger, K. M. and Papich, M. G.}, year={2013}, month={Oct}, pages={471–477} }
 @article{munana_thomas_inzana_nettifee-osborne_mclucas_olby_mariani_early_2012, title={Evaluation of Levetiracetam as Adjunctive Treatment for Refractory Canine Epilepsy: A Randomized, Placebo-Controlled, Crossover Trial}, volume={26}, ISSN={["1939-1676"]}, url={http://www.scopus.com/inward/record.url?eid=2-s2.0-84858746170&partnerID=MN8TOARS}, DOI={10.1111/j.1939-1676.2011.00866.x}, abstractNote={BackgroundThere is little evidence‐based information available to guide treatment of refractory epilepsy in dogs. The antiepileptic drug levetiracetam (LEV) is administered to dogs, although its safety and efficacy are unknown.}, number={2}, journal={JOURNAL OF VETERINARY INTERNAL MEDICINE}, author={Munana, K. R. and Thomas, W. B. and Inzana, K. D. and Nettifee-Osborne, J. A. and McLucas, K. J. and Olby, N. J. and Mariani, C. J. and Early, P. J.}, year={2012}, pages={341–348} }